Publications by authors named "Kim Matthews"

Claim this Profile
P
PET-MRI biomarkers reveal efficacy of a novel NLRP3 inhibitor in Parkinson's disease models.
Eduardo A Albornoz, Karine Mardon, Rajiv Bhalla, Vinod Kumar, Damion H R Stimson, Kim Matthews

Brain· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Macrocyclic NLRP3 Inhibitors.
Stefanie Mesch, Jonathan Shannon, David Miller, Angus MacLeod, Léa Bouché, Kim Matthews

J Med Chem· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial.
Nicola L Brice, Mark Carlton, David H Margolin, Martin Bexon, Kim L Matthews

EClinicalMedicine· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment.
Roland W Bürli, Kevin J Doyle, Louise Dickson, Anna Rowland, Kim Matthews

ACS Med Chem Lett· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist.
Angela Glen, Roland W Bürli, David Livermore, William Buffham, Stephanie Merison, Kim Matthews

Bioorg Med Chem Lett· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterisation of C101248: A novel selective THIK-1 channel inhibitor for the modulation of microglial NLRP3-inflammasome.
Bernardino Ossola, Ali Rifat, Anna Rowland, Helen Hunter, Samuel Drinkall, Kim Matthews

Neuropharmacology· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington's Disease Pathology.
Natsuko Macabuag, William Esmieu, Perla Breccia, Rebecca Jarvis, Wesley Blackaby, Kim Matthews

J Med Chem· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a Potent, Selective, and Brain-Penetrant Rho Kinase Inhibitor and its Activity in a Mouse Model of Huntington's Disease.
Tammy Ladduwahetty, Matthew R Lee, Michel C Maillard, Roger Cachope, Daniel Todd, Kim Matthews

J Med Chem· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson's Disease.
David H Margolin, Nicola L Brice, Antonia M Davidson, Kim L Matthews, Mark B L Carlton

J Pharmacol Exp Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington's Disease.
Amanda Van de Poël, Leticia Toledo-Sherman, Perla Breccia, Roger Cachope, Jennifer R Bate, Kim L Matthews

J Med Chem· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease.
Andrew J Stott, Michel C Maillard, Vahri Beaumont, David Allcock, Omar Aziz, Kim L Matthews

ACS Med Chem Lett· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models.
Leticia Toledo-Sherman, Perla Breccia, Roger Cachope, Jennifer R Bate, Ivan Angulo-Herrera, Kim L Matthews

J Med Chem· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor.
Christopher A Luckhurst, Omar Aziz, Vahri Beaumont, Roland W Bürli, Perla Breccia, Kim L Matthews

Bioorg Med Chem Lett· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Menstrual management in developmentally delayed adolescent females.
Irene Chuah, Alexandra McRae, Kim Matthews, Ann M Maguire, Katharine Steinbeck

Aust N Z J Obstet Gynaecol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors.
Christopher A Luckhurst, Perla Breccia, Andrew J Stott, Omar Aziz, Helen L Birch, Kim L Matthews

ACS Med Chem Lett· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lead optimization toward proof-of-concept tools for Huntington's disease within a 4-(1H-pyrazol-4-yl)pyrimidine class of pan-JNK inhibitors.
John Wityak, Kevin F McGee, Michael P Conlon, Ren Hua Song, Bryan C Duffy, Kim Matthews

J Med Chem· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
Roland W Bürli, Christopher A Luckhurst, Omar Aziz, Kim L Matthews, Dawn Yates

J Med Chem· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo.
Maria Beconi, Omar Aziz, Kim Matthews, Lara Moumné, Catherine O'Connell

PLoS One· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048.
Maria G Beconi, Dawn Yates, Kathryn Lyons, Kim Matthews, Steve Clifton

Drug Metab Dispos· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrazolopyridazine alpha-2-delta-1 ligands for the treatment of neuropathic pain.
James W Myatt, Mark P Healy, Gianpaolo S Bravi, Andrew Billinton, Christopher N Johnson, Kim L Matthews

Bioorg Med Chem Lett· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor.
James M Bailey, Jackie S Scott, Jonathan B Basilla, Victoria J Bolton, Izzy Boyfield, Kim L Matthews

Bioorg Med Chem Lett· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laparoscopic resection of benign ovarian tumours in children with gonadal preservation.
Jonathan Saul Karpelowsky, Erik R La Hei, Kim Matthews

Pediatr Surg Int· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.
Susan M Westaway, Samantha L Brown, Stephen C M Fell, Christopher N Johnson, David T MacPherson, Kim L Matthews

J Med Chem· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.
Susan M Westaway, Samantha L Brown, Elizabeth Conway, Tom D Heightman, Christopher N Johnson, Kim L Matthews

Bioorg Med Chem Lett· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urethral diverticulum in a female child.
Parshotam K Gera, Kim Matthews, Grahame Smith

J Pediatr Urol· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis